544 related articles for article (PubMed ID: 28341900)
21. Oncogenic Osteomalacia From a Primary Phosphaturic Mesenchymal Tumor of the Toe: A Case Report.
Kim I; Rajani R
J Foot Ankle Surg; 2016; 55(2):294-8. PubMed ID: 25441266
[TBL] [Abstract][Full Text] [Related]
22. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23.
Nasu T; Kurisu S; Matsuno S; Tatsumi K; Kakimoto T; Kobayashi M; Nakano Y; Wakasaki H; Furuta H; Nishi M; Sasaki H; Suzuki H; Ito N; Fukumoto S; Nanjo K
Intern Med; 2008; 47(10):957-61. PubMed ID: 18480582
[TBL] [Abstract][Full Text] [Related]
23. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literature.
Jiang Y; Xia WB; Xing XP; Silva BC; Li M; Wang O; Zhang HB; Li F; Jing HL; Zhong DR; Jin J; Gao P; Zhou L; Qi F; Yu W; Bilezikian JP; Meng XW
J Bone Miner Res; 2012 Sep; 27(9):1967-75. PubMed ID: 22532501
[TBL] [Abstract][Full Text] [Related]
24. Tumor induced osteomalacia: A single center experience on 17 patients.
Crotti C; Bartoli F; Coletto LA; Manara M; Marini E; Daolio PA; Parafioriti A; Armiraglio E; Zucchi F; Sinigaglia L; Caporali R; Varenna M
Bone; 2021 Nov; 152():116077. PubMed ID: 34175499
[TBL] [Abstract][Full Text] [Related]
25. Tumour-induced osteomalacia.
Minisola S; Peacock M; Fukumoto S; Cipriani C; Pepe J; Tella SH; Collins MT
Nat Rev Dis Primers; 2017 Jul; 3():17044. PubMed ID: 28703220
[TBL] [Abstract][Full Text] [Related]
26. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed?
Ledford CK; Zelenski NA; Cardona DM; Brigman BE; Eward WC
Clin Orthop Relat Res; 2013 Nov; 471(11):3618-25. PubMed ID: 23868423
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic performance of
Kato A; Nakamoto Y; Ishimori T; Hayakawa N; Ueda M; Temma T; Sano K; Shimizu Y; Saga T; Togashi K
Ann Nucl Med; 2021 Mar; 35(3):397-405. PubMed ID: 33582980
[TBL] [Abstract][Full Text] [Related]
28. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
29. Sphenoid sinus is a rare site for tumor-induced osteomalacia: A case report and literature review.
Wang F; He W; Ma D; Xu W; Xie J; Yuan G
Front Endocrinol (Lausanne); 2023; 14():1116793. PubMed ID: 37033241
[TBL] [Abstract][Full Text] [Related]
30.
El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
[TBL] [Abstract][Full Text] [Related]
31. [Oncogenic osteomalacia and its symptoms: hypophosphatemia, bone pain and pathological fractures].
Kaniuka-Jakubowska S; Biernat W; Sworczak K
Postepy Hig Med Dosw (Online); 2012 Aug; 66():554-67. PubMed ID: 22922156
[TBL] [Abstract][Full Text] [Related]
32. Occipital bone and tumor-induced osteomalacia: a rare tumor site for an uncommon paraneoplastic syndrome.
Colangelo L; Sonato C; Cipriani C; Pepe J; Farinacci G; Palmisano B; Occhiuto M; Riminucci M; Corsi A; Minisola S
Arch Osteoporos; 2023 Jul; 18(1):94. PubMed ID: 37436671
[TBL] [Abstract][Full Text] [Related]
33. Challenges in the management of tumor-induced osteomalacia (TIO).
Brandi ML; Clunie GPR; Houillier P; Jan de Beur SM; Minisola S; Oheim R; Seefried L
Bone; 2021 Nov; 152():116064. PubMed ID: 34147708
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
[TBL] [Abstract][Full Text] [Related]
35. Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23.
Lee JY; Park HS; Han S; Lim JK; Hong N; Park SI; Rhee Y
Yonsei Med J; 2017 Sep; 58(5):981-987. PubMed ID: 28792142
[TBL] [Abstract][Full Text] [Related]
36. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
38. Intracranial phosphaturic mesenchymal tumors. A case report and review of literature.
Kojima D; Ohba S; Abe M; Suzuki A; Horibe S; Tateya I; Hasegawa M; Hirose Y
Neuropathology; 2022 Oct; 42(5):453-458. PubMed ID: 35880350
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia.
Agrawal K; Bhadada S; Mittal BR; Shukla J; Sood A; Bhattacharya A; Bhansali A
Clin Nucl Med; 2015 Jan; 40(1):e6-e10. PubMed ID: 24999675
[TBL] [Abstract][Full Text] [Related]
40. [FGF23 tumor induced osteomalacia with localization of neoplasm in the tympanic cavity].
Ovchinnikov AY; Khon EM; Bakotina AV; Miroshnichenko NA; Gronskaia SA; Belaya ZE
Vestn Otorinolaringol; 2023; 88(6):91-96. PubMed ID: 38153899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
